The IL-23/Th17 Axis in the Immunopathogenesis of Psoriasis
Top Cited Papers
Open Access
- 31 May 2009
- journal article
- review article
- Published by Elsevier BV in Journal of Investigative Dermatology
- Vol. 129 (6), 1339-1350
- https://doi.org/10.1038/jid.2009.59
Abstract
No abstract availableThis publication has 151 references indexed in Scilit:
- Psoriasis Is Characterized by Accumulation of Immunostimulatory and Th1/Th17 Cell-Polarizing Myeloid Dendritic CellsJournal of Investigative Dermatology, 2009
- γδ T cells: an important source of IL-17Current Opinion in Immunology, 2008
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)The Lancet, 2008
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)The Lancet, 2008
- T-Helper 17 Cells in Psoriatic Plaques and Additional Genetic Links between IL-23 and PsoriasisJournal of Investigative Dermatology, 2008
- Inducible IL-23p19 expression in human microglia via p38 MAPK and NF-κB signal pathwaysExperimental and Molecular Pathology, 2008
- T Helper 17 Lineage Differentiation Is Programmed by Orphan Nuclear Receptors RORα and RORγImmunity, 2008
- Distinct regulation of interleukin‐17 in human T helper lymphocytesArthritis & Rheumatism, 2007
- Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cellsNature, 2006
- Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brainNature, 2003